Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

toripalimab 1taletrectinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Non-small Lung Cancer × Clear all
NCT07308106 2026-05-11

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
60 enrolled
Thoracic

Non-small Lung Cancer

NCT06293690 2025-12-18

Toripalimab Combined With SBRT for NSCLC

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Active not recruiting
40 enrolled
Thoracic

Non-small Lung Cancer

NCT07199010 2025-09-30

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting
50 enrolled
Thoracic

Non-small Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡